Effect of incretins on motor deficits in Parkinson disease

Adjusted difference in MDS-UPDRS-3 in GLP1RA-treated vs. placebo (or standard of care) in published clinical trials

A negative value implies an improvement of the MDS-UPDRS-3 at the end of study vs baseline (i.e., symptom severity is reduced), whereas a positive value implies a worsening vs baseline. A confidence interval including 0 indicates no statistical difference vs placebo (or standard of care).
Chart: Created by Jose-Alberto Palma MD PhDSource: Publishd Clinical Trial ResultsEmbed Download imageCreated with Datawrapper